Ibio, INC 10-K annual reports

iBio, Inc. reports progress in its AI-driven antibody development for obesity and cardiometabolic diseases, with its IBIO-600 entering Phase 1 trials and securing substantial funding.

iBio, a preclinical biotechnology company, is leveraging AI to develop precision antibodies for cardiometabolic and obesity diseases, advancing key candidates and securing significant capital.

iBio, Inc. has filed an amendment to its annual report to correct a typographical error in the signature date of the independent auditor's report.

iBio, Inc. transitioned to an AI-powered biotech company focused on precision antibody development, divesting its CDMO facility and forming strategic collaborations.